NCT05055908View on ClinicalTrials.gov

Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors

PHASE3RecruitingINTERVENTIONAL
Enrollment

12,000

Participants

Timeline

Start Date

October 1, 2021

Primary Completion Date

July 1, 2025

Study Completion Date

September 14, 2027

Conditions
Lung Cancer
Interventions
DRUG

Pemetrexed plus Pembrolizumab

Atezolizumab(1200mg) ivgtt, every 21 days, or pembrolizumab, 200mg ivgtt, every 21 days etc. Pemetrexed, 500mg/m2, ivgtt, every 21 days

DRUG

Pembrolizumab

Atezolizumab(1200mg) ivgtt, every 21 days, or pembrolizumab, 200mg ivgtt, every 21 days etc.

DRUG

Pemetrexed

Pemetrexed, 500mg/m2, ivgtt, every 21 days etc.

Trial Locations (1)

410013

RECRUITING

Hunan Cancer Hospital, Changsha

All Listed Sponsors
lead

Hunan Province Tumor Hospital

OTHER